Drug-Drug Interaction Study of Rucaparib, Rosuvastatin and Oral Contraceptives

Inclusion Criteria (All patients): * Willing to sign the ICF and to comply with the study restrictions * Body mass index (BMI) 18.0 to 35.0 kg/m2 * Histologically or cytologically confirmed advanced solid tumor * Patients who, in the opinion of the Investigator, could potentially benefit from treatment with rucaparib * ECOG performance status less than or equal to 1 * Adequate organ function Inclusion Criteria (Arm A): \- Male or female patients ≥ 18 years of age Inclusion Criteria (Arm B): \- Female patients ≥ 18 years of age Exclusion Criteria (All patients): * Specific cancer treatments within 14 days prior to Day 1 * Arterial or venous thrombi (including cerebrovascular accident), myocardial infarction, admission for unstable angina, acute coronary syndrome, cardiac angioplasty, stenting, or poorly controlled hypertension within the last 3 months prior to screening * Pre-existing duodenal stent, recent or existing bowel obstruction * Untreated or symptomatic central nervous system (CNS) metastases. Patients with treated asymptomatic CNS metastases are eligible * Known HIV or AIDS-related illness, acute or history of chronic hepatitis B or C * Female patients who are pregnant or breastfeeding * Participation in another investigational drug trial within 30 days prior to Day 1 or exposure to more than 3 new investigational agents within 12 months prior to Day 1 * Presence of active infection requiring antibiotics * Active second malignancy * History of drug abuse (including alcohol) Exclusion Criteria (Arm A): * Current use of rosuvastatin or any other statin * History of hypersensitivity to rosuvastatin * Current, or history of, clinically significant myopathy Exclusion Criteria (Arm B): * Current use of any 1 of the contraceptive drugs or previous contraceptive implants or depot injections, which may still be clinically effective * History of hypersensitivity to ethinylestradiol or levonorgestrel